146 related articles for article (PubMed ID: 36017147)
1. KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment.
Han Y; Chen J; Wei D; Wang B
Comput Math Methods Med; 2022; 2022():6426800. PubMed ID: 36017147
[TBL] [Abstract][Full Text] [Related]
2. Identification of PTK7 as a promising therapeutic target for thyroid cancer.
Duan F; Tang J; Kong FL; Zou HW; Ni BL; Yu JC
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6809-6817. PubMed ID: 32633373
[TBL] [Abstract][Full Text] [Related]
3. KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.
Hu ZD; Jiang Y; Sun HM; Wang JW; Zhai LL; Yin ZQ; Yan J
Biomed Res Int; 2021; 2021():2676745. PubMed ID: 33490265
[TBL] [Abstract][Full Text] [Related]
4. ASPM promotes migration and invasion of anaplastic thyroid carcinoma by stabilizing KIF11.
Fang Q; Li Q; Qi Y; Pan Z; Feng T; Xin W
Cell Biol Int; 2023 Jul; 47(7):1209-1221. PubMed ID: 36883909
[TBL] [Abstract][Full Text] [Related]
5. KIF11 as a potential cancer prognostic marker promotes tumorigenesis in children with Wilms tumor.
Luo Y; Liu W; Zhu Y; Tian Y; Wu K; Ji L; Ding L; Zhang W; Gao T; Liu X; Zhao J
Pediatr Hematol Oncol; 2022 Mar; 39(2):145-157. PubMed ID: 34378481
[TBL] [Abstract][Full Text] [Related]
6. FK506-binding protein 5 promotes the progression of papillary thyroid carcinoma.
Gao Z; Yu F; Jia H; Ye Z; Yao S
J Int Med Res; 2021 Apr; 49(4):3000605211008325. PubMed ID: 33906532
[TBL] [Abstract][Full Text] [Related]
7. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
8. Kinesin family member 23 (KIF23) contributes to the progression of bladder cancer cells in vitro and in vivo.
Yao DW; Song Q; He XZ
Neoplasma; 2021 Mar; 68(2):298-306. PubMed ID: 33231086
[TBL] [Abstract][Full Text] [Related]
9. tRNA-Derived Fragment tRF-18 Facilitates Cell Proliferation and Inhibits Cell Apoptosis via Modulating KIF1B in Papillary Thyroid Carcinoma.
Lu X; Wu W; Sun D; Sang J
Crit Rev Eukaryot Gene Expr; 2022; 32(5):21-31. PubMed ID: 35993942
[TBL] [Abstract][Full Text] [Related]
10. Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway.
Zhang J; Wei Z; Qi X; Jiang Y; Liu D; Liu K
Funct Integr Genomics; 2023 Aug; 23(3):284. PubMed ID: 37648881
[TBL] [Abstract][Full Text] [Related]
11. KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer.
Zhou J; Chen WR; Yang LC; Wang J; Sun JY; Zhang WW; He ZY; Wu SG
Cancer Res Treat; 2019 Jul; 51(3):1207-1221. PubMed ID: 30590004
[TBL] [Abstract][Full Text] [Related]
12. KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer.
Wei D; Rui B; Qingquan F; Chen C; Ping HY; Xiaoling S; Hao W; Jun G
Int J Biol Sci; 2021; 17(2):514-526. PubMed ID: 33613109
[TBL] [Abstract][Full Text] [Related]
13. KIF11 As a Potential Pan-Cancer Immunological Biomarker Encompassing the Disease Staging, Prognoses, Tumor Microenvironment, and Therapeutic Responses.
Guo X; Zhou L; Wu Y; Li J
Oxid Med Cell Longev; 2022; 2022():2764940. PubMed ID: 36742345
[TBL] [Abstract][Full Text] [Related]
14. High KIF11 expression is associated with poor outcome of NSCLC.
Liu J; Tian Y; Yi L; Gao Z; Lou M; Yuan K
Tumori; 2022 Feb; 108(1):40-46. PubMed ID: 33554761
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.
Sun RF; He N; Zhang GY; Yu ZY; Li LS; Ma ZJ; Jiao ZY
Curr Cancer Drug Targets; 2023; 23(4):293-306. PubMed ID: 35713129
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of KIF11 in TP53 Mutant Glioma Promotes Tumor Stemness and Drug Resistance.
Liu B; Zhang G; Cui S; Du G
Cell Mol Neurobiol; 2022 Jul; 42(5):1477-1485. PubMed ID: 33491154
[TBL] [Abstract][Full Text] [Related]
17. [The mechanism of circ_0023990/miR-873-5p/ANXA2 axis regulating radiosensitivity and development of thyroid carcinoma].
Li HG; Zhao LH; Lu A; Liu JB; Su ZJ; Wang XB; Gao YJ
Zhonghua Yi Xue Za Zhi; 2021 Nov; 101(40):3329-3337. PubMed ID: 34758534
[No Abstract] [Full Text] [Related]
18. KIF11 manipulates SREBP2-dependent mevalonate cross talk to promote tumor progression in pancreatic ductal adenocarcinoma.
Gu X; Zhu Q; Tian G; Song W; Wang T; Wang A; Chen X; Qin S
Cancer Med; 2022 Sep; 11(17):3282-3295. PubMed ID: 35619540
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of kif11 is a poor prognostic factor in clear cell renal cell carcinoma.
Kowalewski A; Jaworski D; Antosik P; Smolińska M; Ligmanowska J; Grzanka D; Szylberg Ł
Pol J Pathol; 2022; 73(2):82-87. PubMed ID: 35979754
[TBL] [Abstract][Full Text] [Related]
20. MTHFD1L knockdown diminished cells growth in papillary thyroid cancer.
Yi D; Yilihamu Y; Jiang C; Wang R; Lu X; Sang J; Su L
Tissue Cell; 2022 Aug; 77():101869. PubMed ID: 35870426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
